In the near future, Europe faces a significant increase in the population at risk of cognitive impairment due to its rapidly aging demographic. However, there is a ray of hope with the emergence of disease-modifying drugs for Alzheimer’s treatment in Europe. Promising treatments like aducanumab, lecanemab, and donanemab have demonstrated the ability to clear amyloid from the brain in the early stages of Alzheimer’s, thereby slowing cognitive decline.
The research on these drugs is progressing rapidly, and if further evidence supports their effectiveness, they could soon become part of clinical practice. Nevertheless, their widespread implementation poses logistical challenges. Ensuring fair access to these drugs and their safe administration will require national health systems to bolster their healthcare infrastructure. This includes recruiting and training a proficient workforce and establishing consistent diagnostic protocols to efficiently utilize imaging and other biomarkers for targeted medication use.
Recognizing the imminent need for timely and accurate diagnosis across health systems, 11 European scientific societies have united to develop a structured workflow for biomarker-based diagnosis of neurocognitive disorders. This collaborative effort aims to streamline the process and facilitate equitable access to innovative treatments for those in need.1
Read more here.
References
- Neurology, L. (2024). Dementia diagnosis in the anti-amyloid era. The Lancet Neurology, 23(3), 219. https://doi.org/10.1016/s1474-4422(24)00041-3
Disclaimers
- The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
